Jeito II S.L.P. → ODYSSEY THERAPEUTICS, INC. ODTX

Jeito II S.L.P. acquired the shares of common stock as described in this Schedule 13D for investment purposes in the regular course of its business. Jeito Capital SAS, as the management company of Jeito II S.L.P., may be deemed to be a beneficial owner, for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Act"), of any securities held by Jeito II S.L.P. Rafaele Tordjman, as Chief Executive Officer of Jeito Capital SAS, and Sabine Dandiguian, as Managing Director of Jeito Capital SAS, may be deemed to be beneficial owners, for purposes of Section 13(d) of the Act, of any securities of the Issuer beneficially owned by Jeito Capital SAS. The Reporting Persons intend to review their investment in the Issuer on a continuing basis. Depending on market conditions, liquidity requirements, the continuing evaluation of the business and prospects of the Issuer and other factors, the Reporting Persons may dispose of or acquire additional shares of common stock of the Issuer. Ksenija Pavletic, who is the General Partner and Chief Commercial Officer at Jeito Capital SAS, is a director of the Issuer. The Reporting Persons, either directly or indirectly through Ms. Pavletic, may engage in discussions from time to time with the Board, the Issuer's management or the Issuer's other stockholders, including discussions that may relate to the items described in clauses (a) through (j) of Item 4 of Schedule 13D. Except as set forth in this Item 4 or Item 6 below, the Reporting Persons have no present plans or proposals that relate to or that would result in any of the actions specified in clauses (a) through (j) of Item 4 of Schedule 13D.